Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral center.","authors":"Philipp Melhorn, Julia Spitzer, Thomas Adel, Ladislaia Wolff, Peter Mazal, Markus Raderer, Barbara Kiesewetter","doi":"10.1007/s00432-025-06126-9","DOIUrl":"10.1007/s00432-025-06126-9","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with metastatic high-grade neuroendocrine neoplasms (NEN) have an unfavorable prognosis. Treatment patterns and therapy outcome are scarcely evidenced, especially considering the WHO classification updates since 2017, and were thus investigated in this study.</p><p><strong>Methods: </strong>This retrospective single-center analysis evaluated patients with neuroendocrine tumors grade 3 (NET G3) or neuroendocrine carcinomas (NEC) treated at the Medical University of Vienna since 2010. The primary endpoints were progression-free survival (PFS) and overall survival (OS) following first-line treatment.</p><p><strong>Results: </strong>A total of 80 patients were included, 53 (66%) had NEC and 27 (34%) NET G3. Thirty patients had pancreatic NEN (38%), 29 gastrointestinal NEN (36%), 20 an unknown primary (25%), and one gall bladder NEC. All patients had metastatic disease, and all but four received systemic therapy. Platinum/etoposide was the most frequent palliative first-line treatment in NEC (41/47, 87%) and capecitabine/temozolomide (CAPTEM) in NET G3 (14/27, 52%). Overall, the median PFS and OS from first line start were 16.1 and 43.9 months for NET G3 and 6.1 and 12.7 months for NEC, respectively. Median PFS for platin/etoposide in NEC was 6.1 months (overall response rate [ORR] 56%) and for CAPTEM in NET G3 16.9 months (ORR 46%). Irrespective of the limited sample size (n = 4-11), second-line median PFS was short in NEC (FOLFIRI 2.8, FOLFOX 2.6, CAPTEM 5.4, other 2.6 months) and longer in NET G3 (8.2-11.1 months).</p><p><strong>Conclusions: </strong>The present data from a large European NET center show that multiple treatment strategies are used in NEN and highlight the varying outcomes between NET G3 and NEC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"86"},"PeriodicalIF":2.7,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11839849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy.","authors":"Yi Chen, David Pasquier, Damon Verstappen, Henry C Woodruff, Philippe Lambin","doi":"10.1007/s00432-025-06119-8","DOIUrl":"10.1007/s00432-025-06119-8","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) remains a global health concern, marked by increasing incidence rates and poor outcomes. This study seeks to develop a robust predictive model by integrating radiomics and deep learning features with clinical data to predict 2-year survival in HCC patients treated with stereotactic body radiation therapy (SBRT).</p><p><strong>Methods: </strong>This study analyzed a cohort of 186 HCC patients who underwent SBRT. Radiomics features were extracted from CT scans, complemented by collection of clinical data. Training and validation of machine learning models were conducted using nested cross-validation techniques. Deep learning models, leveraging various convolutional neural networks (CNNs), were employed to effectively integrate both image and clinical data. Post-hoc explainability techniques were applied to elucidate the contribution of imaging data to predictive outcomes.</p><p><strong>Results: </strong>Handcrafted radiomics features demonstrated moderate predictive performance, with area under the receiver operating characteristic curve (AUC) values ranging from 0.59 to 0.72. Deep learning models, harnessing the fusion of image and clinical data, exhibited improved predictive accuracy, with AUC values ranging from 0.71 to 0.81. Notably, the ensemble model, amalgamating handcrafted radiomics and deep learning features with clinical data, demonstrated the most robust predictive capability, achieving an AUC of 0.86 (95% CI: 0.80-0.93).</p><p><strong>Conclusion: </strong>The ensemble model represents a significant advancement, providing a comprehensive tool for predicting survival outcomes in HCC patients undergoing SBRT. The inclusion of interpretability methods such as Grad-CAM enhances transparency and understanding of these complex predictive models.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"84"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of breast cancer tissue with optical coherence tomography: key findings from a large-scale study.","authors":"Xiaojing Liu, Miao Cui, Cuixia Feng, Shujuan Jin, Xiaowei Han, Yongfang Wu, Di Meng, Si Zuo, Qing Xu, YanHong Tai, Feng Liang","doi":"10.1007/s00432-025-06125-w","DOIUrl":"10.1007/s00432-025-06125-w","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer patients undergoing breast-conserving surgery may require a second operation if positive margins persist but current intraoperative methodologies often lack real-time and comprehensive assessments of tissue margins. This study addresses this critical gap by introducing a novel approach to enhance margin assessment in breast surgery.</p><p><strong>Methods: </strong>A total of 252 fresh tissue blocks from 199 patients with different types of breast lesions were scanned with a customized swept-source optical coherence tomography (SS-OCT) system, and the OCT features of normal, benign, and malignant breast tissues, were systematically analyzed.</p><p><strong>Results: </strong>The qualitative analysis results revealed that adipose tissue has high penetration depth and a typical honeycomb pattern, whereas fibrous tissue has the brightest grayscale values and a bundle-like structure. The lobular area appears as a dark region, and dilated ducts present a distinct tubular structure on B-scan images. Adenosis results in bright areas, fibroadenoma results in typical contour structures, phyllodes tumors present lobular structures, invasive carcinomas present a stellate pattern and low penetration depth, and mucinous carcinoma cancer cells are clearly visible within the low-scattering mucin.</p><p><strong>Conclusions: </strong>Importantly, we provide comparative OCT and hematoxylin and eosin (H&E) histology images for less common conditions, such as phyllodes tumors, intraductal papillomas, and mucinous carcinoma. For the first time, we established an 3D OCT-histopathology library with a large field of view and systematically analyzed the multidimensional features. This work strongly supports the feasibility of using OCT technology intraoperatively in surgery. Additionally, the OCT-histopathology library can help pathologists better understand and identify tissue features, thereby enhancing diagnostic efficiency.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"83"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature.","authors":"Jin Sheng, Juan Jiao, Na Yan, Hongming Pan","doi":"10.1007/s00432-025-06132-x","DOIUrl":"10.1007/s00432-025-06132-x","url":null,"abstract":"<p><p>Primary MET amplification is an infrequent tumorigenic driver gene alteration identified in pulmonary neoplasms. Data on the effectiveness of MET-tyrosine kinase inhibitor (TKI) therapy in de novo MET amplification are relatively scarce, and there remains a dearth of empirical evidence supporting the use of precision therapy as first-line treatment for advanced non-small cell lung cancer (NSCLC) with primary MET amplification. We present a case of advanced lung adenocarcinoma in an elderly patient with primary MET amplification. The patient had an initial ECOG Performance Status (PS) 2. DNA-NGS analysis of tissue samples revealed a MET gene copy number (GCN) of 8, indicating MET amplification, without other oncogenic mutations associated with available drugs being detected. This finding was validated by MET fluorescence in situ hybridization (FISH), which showed cluster amplification. Initial treatment with savolitinib resulted in a sustained partial response lasting more than sixteen months. Our results suggest that savolitinib is effective and safe for the treatment of elderly patients with de novo amplified MET metastatic NSCLC and may therefore be considered a potential treatment option worthy of prospective study confirmation.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"82"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brown adipose tissue activity on PET/CT and the course of Hodgkin lymphoma.","authors":"Taner Tan, Hülya Seymen, Sinem Civriz Bozdağ, Olga Meltem Akay, A Umur Topçu","doi":"10.1007/s00432-024-06076-8","DOIUrl":"10.1007/s00432-024-06076-8","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"85"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Melanoma genomics- will we go beyond BRAF in clinics?","authors":"Justyna Mirek, Wiesław Bal, Magdalena Olbryt","doi":"10.1007/s00432-025-06112-1","DOIUrl":"10.1007/s00432-025-06112-1","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"81"},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Mechanistic insights into ¹²⁵I seed implantation therapy for Cholangiocarcinoma: focus on ROS-Mediated apoptosis and the role of GPX2.","authors":"Jun Luo, Zheng Yao, Weiren Liang, Danjun Song, Hui Zeng, Yi Jiang, Zhehan Bao, Jiaping Zheng, Yinan Ding","doi":"10.1007/s00432-025-06111-2","DOIUrl":"10.1007/s00432-025-06111-2","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"80"},"PeriodicalIF":2.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11825609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.","authors":"Mengchao Wang, Shao Zhang, Dan Yi, Yan Ou, Shuqi Xie, Chuanxiu Zeng, Xueqian Qin, Lu Zhao, Zhen Wang, Fanming Kong, Liwei Chen","doi":"10.1007/s00432-025-06115-y","DOIUrl":"10.1007/s00432-025-06115-y","url":null,"abstract":"<p><p>The cellular-mesenchymal to epithelial transition factor (MET) gene plays a crucial role in maintaining cell homeostasis, motility, and apoptosis. In cancer, MET gene alterations promote tumour cell proliferation, invasion and metastasis. In non-small cell lung cancer (NSCLC), MET gene alterations include MET exon 14 (METex14) skipping mutation (METΔ14ex), MET amplification (METamp), MET fusion, and MET tyrosine kinase domain missense mutations (MET-TKD) and MET protein overexpression. Among them, the METΔ14ex is an independent driver gene of NSCLC. Three to four per cent of NSCLC patients carry METΔ14ex, and these patients have a poor prognosis and respond poorly to conventional chemotherapy. Small molecule highly selective MET inhibitors such as carmatinib, tepotinib, and cervotinib have shown promising efficacy and safety in clinical trials. Monoclonal antibodies, bispecific antibodies, antibody conjugate drugs, and immune checkpoint inhibitors provide more treatment space for patients with METΔ14ex. In this review, we summarize the current application and research of MET inhibitors and immune checkpoint inhibitors in NSCLC with METΔ14ex and provide recommendations for precise treatment of NSCLC patients with MET gene changes mutations. It also provides new ideas for solving the problems of synergistic effect and drug resistance in targeted therapy and immunotherapy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"78"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering the stromal molecular landscape: the correlation between p16 and α-SMA in epithelial ovarian cancer.","authors":"Marta Caretto, Angiolo Gadducci, Sabina Pistolesi, Diletta Mattiussi Tome, Giuseppe Nicolò Fanelli, Antonio Giuseppe Naccarato, Tommaso Simoncini","doi":"10.1007/s00432-025-06120-1","DOIUrl":"10.1007/s00432-025-06120-1","url":null,"abstract":"<p><strong>Introduction: </strong>The tumor microenvironment (TME) plays an essential role in promoting cancer initiation, progression and metastasis. Cancer-associated fibroblasts (CAFs) are a major constituent of the TME, but universal CAFs' markers have not yet been identified. We selected several new biomarkers [p16 and α-smooth muscle actin (α-SMA)] to investigate the molecular landscape in epithelial ovarian cancer (EOC), given to the unique TME of this malignancy.</p><p><strong>Methods: </strong>In total, 64 patients with a diagnosis of EOC who underwent primary debulking surgery (PDS) at the Department of Gynecology and Obstetrics of the University of Pisa were enrolled between January 2019 and June 2021. The stromal expression of α-SMA and p16 was investigated by using immunohistochemistry, and the correlations between p16 and α-SMA immunoreactivity and BRCA mutational status were analyzed.</p><p><strong>Results: </strong>Positive p16 stromal expression was found in 6 out of 38 (15,78%) patients with wild-type BRCA and in only 1 of the 22 (4,50%) patients with mutated BRCA. Conversely, positive α-SMA expression was detected in 34 of 38 patients with wild-type BRCA (89,47%) and in 21 of 22 patients (95,45%) with mutated BRCA. There was a significant difference (r = -0,32) between the negative stromal p16 expression and the positive stromal expression of α-SMA.</p><p><strong>Conclusion: </strong>This study suggests a new correlation between stromal expression of p16 and α-SMA and BRCA mutational status in EOC. Further investigations are strongly warranted to improve the understanding of the landscape of this malignancy.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"79"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11821793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis.","authors":"Zhenli Li, Tiezhu Yao, Guang Liu, Zhengkun Guan, Jing Liu, Ling Guo, Jingtao Ma","doi":"10.1007/s00432-025-06110-3","DOIUrl":"10.1007/s00432-025-06110-3","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 2","pages":"74"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11814047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}